274 related articles for article (PubMed ID: 31523950)
1. Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance.
Gaglia J; Kissler S
Biochemistry; 2019 Oct; 58(40):4107-4111. PubMed ID: 31523950
[TBL] [Abstract][Full Text] [Related]
2. Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes.
Mignogna C; Maddaloni E; D'Onofrio L; Buzzetti R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1209-1219. PubMed ID: 34936848
[TBL] [Abstract][Full Text] [Related]
3. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
Chatenoud L; Waldmann H
Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
[TBL] [Abstract][Full Text] [Related]
4. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD3 monoclonal antibodies for the prevention and treatment of type 1 diabetes: A literature review.
LeFevre JD; Cyriac SL; Tokmic A; Pitlick JM
Am J Health Syst Pharm; 2022 Nov; 79(23):2099-2117. PubMed ID: 36056809
[TBL] [Abstract][Full Text] [Related]
6. Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases.
Dean Y; Dépis F; Kosco-Vilbois M
Swiss Med Wkly; 2012; 142():w13711. PubMed ID: 23254986
[TBL] [Abstract][Full Text] [Related]
7. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
Long SA; Thorpe J; Herold KC; Ehlers M; Sanda S; Lim N; Linsley PS; Nepom GT; Harris KM
Cell Immunol; 2017 Sep; 319():3-9. PubMed ID: 28844471
[TBL] [Abstract][Full Text] [Related]
8. Prevention versus intervention of type 1 diabetes.
Brooks-Worrell B; Palmer JP
Clin Immunol; 2013 Dec; 149(3):332-8. PubMed ID: 23803322
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.
Skyler JS; Pugliese A
Diabetes Technol Ther; 2013 Jun; 15 Suppl 2(Suppl 2):S2-13-S2-20. PubMed ID: 23786294
[TBL] [Abstract][Full Text] [Related]
10. Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis.
Kamrul-Hasan ABM; Mondal S; Nagendra L; Yadav A; Aalpona FTZ; Dutta D
Endocr Pract; 2024 May; 30(5):431-440. PubMed ID: 38519028
[TBL] [Abstract][Full Text] [Related]
11. Changing the landscape for type 1 diabetes: the first step to prevention.
Dayan CM; Korah M; Tatovic D; Bundy BN; Herold KC
Lancet; 2019 Oct; 394(10205):1286-1296. PubMed ID: 31533907
[TBL] [Abstract][Full Text] [Related]
12. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.
Simmons K; Michels AW
Rheum Dis Clin North Am; 2014 Nov; 40(4):797-811. PubMed ID: 25437293
[TBL] [Abstract][Full Text] [Related]
13. Prevention of type 1 diabetes: where we are and where we are going.
Frontino G; Guercio Nuzio S; Scaramuzza A; D'Annunzio G; Toni S; Citriniti F; Bonfanti R
Minerva Pediatr (Torino); 2021 Dec; 73(6):486-503. PubMed ID: 34286946
[TBL] [Abstract][Full Text] [Related]
14. Timing of Immunotherapy in Type 1 Diabetes: The Earlier, the Better?
Felton JL
Immunohorizons; 2021 Jul; 5(7):535-542. PubMed ID: 34261674
[TBL] [Abstract][Full Text] [Related]
15. Immune therapy and β-cell death in type 1 diabetes.
Lebastchi J; Deng S; Lebastchi AH; Beshar I; Gitelman S; Willi S; Gottlieb P; Akirav EM; Bluestone JA; Herold KC
Diabetes; 2013 May; 62(5):1676-80. PubMed ID: 23423576
[TBL] [Abstract][Full Text] [Related]
16. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
Perdigoto AL; Preston-Hurlburt P; Clark P; Long SA; Linsley PS; Harris KM; Gitelman SE; Greenbaum CJ; Gottlieb PA; Hagopian W; Woodwyk A; Dziura J; Herold KC;
Diabetologia; 2019 Apr; 62(4):655-664. PubMed ID: 30569273
[TBL] [Abstract][Full Text] [Related]
17. Humanizing animal models: a key to autoimmune diabetes treatment.
Bresson D; von Herrath M
Sci Transl Med; 2011 Feb; 3(68):68ps4. PubMed ID: 21289271
[TBL] [Abstract][Full Text] [Related]
18. Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.
Tooley JE; Vudattu N; Choi J; Cotsapas C; Devine L; Raddassi K; Ehlers MR; McNamara JG; Harris KM; Kanaparthi S; Phippard D; Herold KC
Eur J Immunol; 2016 Jan; 46(1):230-41. PubMed ID: 26518356
[TBL] [Abstract][Full Text] [Related]
19. Teplizumab for treatment of type 1 diabetes mellitus.
Skelley JW; Elmore LK; Kyle JA
Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD3 clinical trials in type 1 diabetes mellitus.
Daifotis AG; Koenig S; Chatenoud L; Herold KC
Clin Immunol; 2013 Dec; 149(3):268-78. PubMed ID: 23726024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
